LEND: Intranasal Oxytocin for the Treatment of Children and Adolescents with Autism Spectrum Disorders (ASD).
Project Description:
We are studying an investigational drug called intranasal oxytocin (Syntocinon). Syntocinon has been approved by the U.S. Food and Drug Administration for use in helping women breastfeed, but it has not been approved for use in children with ASD. However, there is previous research conducted that has indicated that after administration of oxytocin, adults with ASD demonstrated improvements in social cognition, and reduced repetitive behaviours and anxiety. There is also early research to suggest that children may also benefit in these areas. The purpose of this study is to test if oxytocin works to help children and adolescents with ASD. Suma Jacob acts as PI, and Amy esler is Co-PI. Sunday Francis, LEND Post Doc Trainee, serves as Lab and Project manager.
Keyword(s):
Autism, Ocytocin
Core Function(s):
Performing Direct and/or Demonstration Services, Performing Research or Evaluation
Target Audience:
Students/Trainees (long or intermediate trainees), Community Trainees / Short term trainees, Professionals and Para-Professionals, Legislators/Policy Makers
Unserved or Under-served Populations:
Specific Groups
Primary Target Audience Geographic Descriptor:
National
COVID-19 Related Data:
N/A